Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 390

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 390
---
)                                                                 | -167 |    — | -1,526 |
| Opella                                                                       |    — |    — |    -35 |
| Research and development projects and technology platforms(b)(c)(d)          |  415 |  896 |  1,107 |
| Others                                                                       |   17 |   36 |      — |

(a) For 2024, this comprises a reversal of € 167million in connection with the disposal of Enjaymo.

For 2022, this amount mainly comprises a reversal of € 2,154million of impairment losses taken against Eloctate and BIVV001 (assets belonging to the

Eloctate franchise), consisting of € 1,554million for marketed products and € 600million for research and development projects respectively. In 2019,

the launch of competing products for Eloctate led Sanofi to update its sales forecasts for products belonging to the franchise, as a result of which

impairment losses of € 2.8billion were recognized against the assets in question. The reversal reflects the approval by the FDA on February 22, 2023 of

ALTUVIIIO (the commercial name of efanesoctocog alpha, corresponding to the BIVV001 project), which was submitted in 2022.

(b) For 2024, the monitoring of impairment indicators for other intangible assets led to the recognition of net impairment losses of € 415million , comprising

(i) impairment losses of € 640million against various research and development projects - including a € 239million loss resulting from the decision taken

in February 2025 to discontinue a phase 3 clinical study investigating of a vaccine candidate to prevent invasive E.coli disease - and (ii) an impairment

reversal of € 225million recognized in connection with the disposal of the ProXTen technology platform.

(c) For 2023, this amount mainly comprises an impairment loss of € 833million , reflecting the impact of the strategic decision to de-prioritize certain R&D

programs, in particular those related to the NK Cell and ProXTen technology platforms.

(d) For 2022, this amount mainly comprises:

– an impairment loss of € 1,586million taken against the development project for SAR444245 (non-alpha interleukin-2), recognized following revised

cash flow projections reflecting unfavorable developments in the launch schedule;

– the € 600million reversal relating to the BIVV